At Genezen, our mission is simple: to provide quality viral vector production and help deliver life-changing therapies to patients.
We’re an ambitious contract development and manufacturing organization (CDMO) with unique historic expertise in lentiviral and retroviral vectors. Offering process development, GMP viral vector manufacturing, and cell line and assay testing services, we act with care to realize the immense potential of your products through proactive problem solving and the delivery of exceptional gene and cell therapy quality.
We aim to deliver flexible support that molds to our customers’ needs wherever they are in their journey, leveraging deep expertise to develop tailored processes and ensuring that everything we do is meaningfully focused on getting your viral vector where it needs to go. With customer service at our core – we strive to be open, collaborative and welcoming – it’s how we do business because we care about you, your product and your success.
We will be an integral part of creating a world where cell and gene therapy is a regular, accessible path to helping people get better. It’s hard to find a more noble and meaningful purpose, and we fix our eyes to that finish in our everyday work.
Meet our People
Our team is dedicated to getting your viral vector where it needs to go. Communication and collaboration are part of our DNA and we can't wait to talk to you about your current challenges and needs.
See how we got here
Founded in 2014 by current Chairman Bill Vincent, our history is packed with innovation and ambition. Following investment by Ampersand Capital Partners’ in 2021, Genezen catapulted forward built on a foundation of expansive knowledge in lentiviral and retroviral vector production.
See our vacancies
Join the team
We want our employees to be innovative, collaborative problem solvers who are dedicated to meeting the challenges of our clients and a fast-growing market.
Latest GMP Vector Manufacturing Insights
Stable cell lines vs transient transfection…
The aim of upstream processing in viral vector development and manufacturing...Read more
Genezen Delivers Next Phase of cGMP…
October 3, 2022 – Genezen, a cell and gene therapy Contract...Read more
Genezen, Monon Bioventures, and Purdue University…
September 22, 2022 – Glioblastoma is one of the most aggressive...Read more